2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Status
Recruiting
4
Completed
4
Sponsor Class
INDUSTRY
4
Study Type
Interventional
4
Sponsor
Cancer Type
Genitourinary
4
Conditions
Prostatic Neoplasms
4
Interventions
Cyclophosphamide
1499
Cisplatin
1435
Paclitaxel
1340
Radiotherapy
1310
Carboplatin
1267
Gemcitabine
1226
Docetaxel
1133
Bevacizumab
1070
Fluorouracil
906
Doxorubicin
805
Dexamethasone
755
Rituximab
744
Capecitabine
735
Oxaliplatin
709
pembrolizumab
700
Etoposide
679
Irinotecan
639
Filgrastim
624
Cytarabine
587
Nivolumab
586
Leucovorin
583
Vincristine
517
Cetuximab
479
Prednisone
478
Bortezomib
474
Trastuzumab
468
Erlotinib Hydrochloride
467
Surveys and Questionnaires
460
Methotrexate
444
Lenalidomide
436
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
4 trials
Recent
Start date
Enrollment
Completed
×
fludrocortisone acetate
×
Clear all
NCT06104449
2026-04-27
MK-5684-005
Merck Sharp & Dohme LLC
Phase 1
Completed
7 enrolled
NCT06136598
2026-03-19
MK-5684-001
Merck Sharp & Dohme LLC
Phase 1
Completed
14 enrolled
NCT06566989
2024-10-23
MK-5684-008
Merck Sharp & Dohme LLC
Phase 1
Completed
8 enrolled
NCT06554639
2024-10-15
MK-5684-011
Merck Sharp & Dohme LLC
Phase 1
Completed
12 enrolled